Your browser doesn't support javascript.
loading
Importance of beta cell mass for glycaemic control in people with type 1 diabetes.
Jansen, Theodorus J P; Brom, Maarten; Boss, Marti; Buitinga, Mijke; Tack, Cees J; van Meijel, Lian A; de Galan, Bastiaan E; Gotthardt, Martin.
Afiliação
  • Jansen TJP; Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Brom M; Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Boss M; Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands. marti.boss@radboudumc.nl.
  • Buitinga M; Nutrition and Movement Sciences, Maastricht University, Maastricht, the Netherlands.
  • Tack CJ; Radiology and Nuclear Medicine, Maastricht UMC+, Maastricht, the Netherlands.
  • van Meijel LA; Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • de Galan BE; Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Gotthardt M; Internal Medicine, Maxima Medical Center, Veldhoven, the Netherlands.
Diabetologia ; 66(2): 367-375, 2023 02.
Article em En | MEDLINE | ID: mdl-36394644
ABSTRACT
AIMS/

HYPOTHESIS:

The role of beta cell mass in the balance of glucose control and hypoglycaemic burden in people with type 1 diabetes is unclear. We applied positron emission tomography (PET) imaging with radiolabelled exendin to compare beta cell mass among people with type 1 diabetes and either low glucose variability (LGV) or high glucose variability (HGV).

METHODS:

All participants with either LGV (n=9) or HGV (n=7) underwent a mixed-meal tolerance test to determine beta cell function and wore a blinded continuous glucose monitor for a week. After an i.v. injection with [68Ga]Ga-NODAGA-exendin-4, PET images were acquired for the quantification of pancreatic uptake of radiolabelled exendin. The mean standardised uptake value (SUVmean) of the pancreas was used to determine the amount of beta cell mass.

RESULTS:

Participants with LGV had lower HbA1c (46.0 mmol/mol [44.5-52.5] [6.4% (6.3-7)] vs 80 mmol/mol [69.0-110] [9.5% (8.5-12.2)], p=0.001) and higher time in range (TIR) (75.6% [73.5-90.3] vs 38.7% [25.1-48.5], p=0.002) than those with HGV. The SUVmean of the pancreas was higher for the LGV than for the HGV group (5.1 [3.6-5.6] vs 2.9 [2.1-3.4], p=0.008). The AUCC-peptideAUCglucose ratio was numerically, but not statistically, higher in the LGV compared with the HGV group (2.7×10-2 [6.2×10-4-5.3×10-2] vs 9.3×10-4 [4.7×10-4-5.2×10-3], p=0.21). SUVmean correlated with the AUCC-peptideAUCglucose ratio (Pearson r=0.64, p=0.01), as well as with the TIR (r=0.64, p=0.01) and the SD of interstitial glucose levels (r=-0.66, p=0.007). CONCLUSION/

INTERPRETATION:

Our data show higher beta cell mass in people with type 1 diabetes and LGV than in those with HGV, independent of beta cell function.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Limite: Humans Idioma: En Revista: Diabetologia Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Limite: Humans Idioma: En Revista: Diabetologia Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda